Deciphering the mechanisms by which parasites develop inside hepatocytes is an important step toward the understanding of malaria pathogenesis. We propose that the nature and the magnitude of the inflammatory response in the liver are key for the establishment of the infection. Here, we used mice deficient in the multidrug resistance-2 gene (Mdr2)-encoded phospholipid flippase leading to the development of liver inflammation. Infection of Mdr2 mice with ANKA (ANKA) sporozoites (SPZ) resulted in the blockade of hepatic exo-erythrocytic forms (EEFs) with no further development into blood stage parasites. Interestingly, cultured primary hepatocytes from mutant and wild-type mice are equally effective in supporting EEF development. The abortive infection resulted in a long-lasting immunity in Mdr2 mice against infectious SPZ where neutrophils and IL-6 appear as key effector components along with CD8 and CD4 effector and central memory T cells. Inflammation-induced breakdown of liver tolerance promotes anti-parasite immunity and provides new approaches for the design of effective vaccines against malaria disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710885PMC
http://dx.doi.org/10.3389/fimmu.2020.585502DOI Listing

Publication Analysis

Top Keywords

mdr2 mice
8
hepatic inflammation
4
inflammation confers
4
confers protective
4
protective immunity
4
liver
4
immunity liver
4
liver stages
4
stages malaria
4
malaria parasite
4

Similar Publications

[Study on the mechanism of Fuzheng Huayu formula against biliary fibrosis in mice].

Zhonghua Gan Zang Bing Za Zhi

November 2024

Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai201203, China Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Medicine, Shanghai201203, China.

Article Synopsis
  • The study aimed to explore how the Fuzheng huayu formula (FZHY) affects biliary fibrosis in mice by comparing its effects with obeticholic acid (OCA) and a control group.
  • Mice were treated with specific drugs over a 12-week period, and various liver health indicators, including serum enzyme levels and tissue markers, were analyzed using multiple biochemical techniques.
  • Results demonstrated that both FZHY and OCA effectively reduced the harmful effects of fibrosis in the gene knockout mice by reversing elevated liver indicators, improving markers of liver function, and influencing specific molecular pathways related to inflammation and cellular response.
View Article and Find Full Text PDF

Background: Fibroinflammatory cholangiopathies, such as primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), are characterized by inflammation and biliary fibrosis, driving disease-related complications. In biliary fibrosis, cholangiocytes activated by transforming growth factor-β (TGFβ) release signals that recruit immune cells to drive inflammation and activate hepatic myofibroblasts to deposit the extracellular matrix (ECM). TGFβ regulates stearoyl-CoA desaturase (SCD), an enzyme that catalyzes the synthesis of monounsaturated fatty acids, in stimulating fibroinflammatory lipid signaling.

View Article and Find Full Text PDF
Article Synopsis
  • - Cholangiopathies are complex disorders with limited understanding and no effective treatments, prompting a study on the extrahepatic biliary tree (EHBD) in Mdr2 mice, a cholestatic mouse model, across different ages (2 to 40 weeks).
  • - The study assessed the effects of N-acetyl-L-Cysteine (NAC), an antioxidant and glutathione precursor, on EHBD injury both ex vivo (using bile duct samples) and in vivo (through oral administration for three weeks).
  • - Results showed that NAC treatment improved bile duct morphology and reduced liver fibrosis along with lower liver enzyme levels, suggesting a shift in cellular state from apoptosis to proliferation, indicating NAC's potential as a therapeutic
View Article and Find Full Text PDF

Serum metabonomics reveal the effectiveness of human placental mesenchymal stem cell therapy for primary sclerosing cholangitis.

Stem Cell Res Ther

October 2024

State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou City, 310003, China.

Article Synopsis
  • The study looks at how a type of stem cell treatment from the placenta can help patients with a liver disease called primary sclerosing cholangitis (PSC).
  • Researchers used special mice to see how the stem cell treatment affected their liver health and identified important substances in their blood to check its effectiveness.
  • They found that after the treatment, certain harmful substances in the liver decreased while beneficial ones increased, suggesting the stem cell treatment was successful in improving liver function.
View Article and Find Full Text PDF

Liver fibrosis associated with increased mortality is caused by activation of hepatic stellate cells and excessive production and accumulation of extracellular matrix in response to fibrotic insults. It has been shown that in addition to liver inflammation, systemic inflammation also contributes to liver fibrogenesis. A deeper understanding of mechanisms that control liver fibrotic response to intra- and extra-hepatic inflammation is essential to develop novel clinical strategies against this disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!